Showing results (1-10 of 47) with videos related to
Sort By:
Pageof 5
Clinical Lymphoma, Myeloma & Leukemia|December 1, 2010
Classification and risk stratification for acute promyelocytic leukemiaSteven CoutrePediatric Blood & Cancer|November 25, 2014
A pediatric case of T-cell prolymphocytic leukemiaBryan Mitton, Steven Coutre, Jennifer Willert, et al.Blood Advances|August 12, 2018
Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17pJames I Barnes, Vasu Divi, Adrian Begaye, et al.Haematologica|October 14, 2011
Treatment advances have not improved the early death rate in acute promyelocytic leukemiaJames Scott McClellan, Holbrook E Kohrt, Steven Coutre, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2012
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemiaRobert J Kreitman, Martin S Tallman, Tadeusz Robak, et al.Cancer|January 3, 2013
Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trialNicole Lamanna, Leonard T Heffner, Matt Kalaycio, et al.British Journal of Haematology|March 4, 2014
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemiaAnjali S Advani, Shannon McDonough, Steven Coutre, et al.Blood|April 6, 2018
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studiesAbby Statler, Megan Othus, Harry P Erba, et al.Blood|May 15, 2007
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 studyOliver Ottmann, Hervé Dombret, Giovanni Martinelli, et al.Blood|March 1, 2018
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-upRobert J Kreitman, Martin S Tallman, Tadeusz Robak, et al.Pageof 5